Cantab Pharmaceuticals plc announced that it has agreed tocollaborate with Cancer Research Campaign Technology Ltd.(CRC Technology, which is the commercialization arm for CRC-funded research) on developing an immunotherapeutic productfor treating genital warts.
Cantab of Cambridge, England, has an option to acquireexclusive worldwide rights to a family of patent applications onthe use of papillomavirus proteins for treating ano-genitalwarts, cervical cancer and laryngeal cancer. Researchers at theBeatson Institute of Cancer Research, Glasgow, and theUniversity of Glasgow are the inventors.
Cantab (NASDAQ:CNTBY) researchers, in collaboration with theBeatson Institute and other colleagues, are already developingan engineered human papillomavirus protein-based product,TA-GW, which is designed to be administered in conjunctionwith an adjuvant to patients with multiple or persistent genitalwarts. If the preliminary studies are successful, Cantab intendsto license CRC Technology's patent applications. -- Jennifer VanBrunt
(c) 1997 American Health Consultants. All rights reserved.